Third Section: Design of a dimeric-nanobody specific for Aβ42 oligomers: the Dimeric-DesAb-O
- Liliana Napolitano
- © 2026 Author(s) |
- CC BY 4.0
- DOI: 10.36253/979-12-215-0993-9.06
This chapter describes the rational design and characterization of Dimeric-DesAb-O, engineered to target Aβ42 oligomers. Real-Time Based ELISA assay and Thioflavin T (ThT) assays confirm that dimerization enhances binding affinity and slows Aβ42 aggregation, while Transmission Electron Microscopy (TEM) shows reduced fibril diameter. Dimeric-DesAb-O selectively detects oligomers in AD patient CSF and neutralizes neurotoxicity more effectively than the monomer. These results prove that rational dimerization improves target engagement, offering a potent strategy for AD diagnosis and therapy.
- Keywords:
- Alzheimer’s disease,
- Aβ42 oligomers,
- Single-domain antibodies,
- Rational dimerization,
- Binding specificity,
- Neurotoxicity neutralization,
- ORCID: 0009-0004-3087-286X
Chapter Information
Chapter Title
Third Section: Design of a dimeric-nanobody specific for Aβ42 oligomers: the Dimeric-DesAb-O
Authors
Liliana Napolitano
Language
English
DOI
10.36253/979-12-215-0993-9.06
Peer Reviewed
Publication Year
2026
Copyright Information
© 2026 Author(s)
Content License
Metadata License
Bibliographic Information
Book Title
A multidisciplinary approach for the early diagnosis of Alzheimer’s disease and potential therapeutic applications
Authors
Liliana Napolitano
Peer Reviewed
Number of Pages
184
Publication Year
2026
Copyright Information
© 2026 Author(s)
Content License
Metadata License
Publisher Name
Firenze University Press
DOI
10.36253/979-12-215-0993-9
ISBN Print
979-12-215-0992-2
eISBN (pdf)
979-12-215-0993-9
eISBN (xml)
979-12-215-0994-6
Series Title
Premio Tesi di Dottorato Città di Firenze
Series ISSN
3103-3881
Series E-ISSN
3103-3989